Combination therapy study for multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether adding a Chinese herbal formula (Yishen Daluo Yin) to standard multiple sclerosis medications helps manage the disease better. It may be an option if you have relapsing MS and are stable on a first-line drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have relapsing-remitting multiple sclerosis (not the progressive type)
- You have not had a relapse in the last 30 days
- You are taking a stable dose of a first-line MS medication (like teriflunomide, dimethyl fumarate, fingolimod, or others listed)
- You are not pregnant or breastfeeding
- You can tolerate MRI scans with contrast dye
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a traditional Chinese medicine granule called Yishen Daluo Yin for people with relapsing-remitting multiple sclerosis (RRMS). The goal is to see if it reduces relapses and is safe. You may qualify if you have had MS flare-ups recently but are currently stable.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
This study tests whether adding a probiotic supplement to your usual MS treatment (or to no treatment) can help manage relapsing-remitting multiple sclerosis. It aims to see if the probiotic is safe and beneficial as an add-on therapy.
This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
Hear when a new RRMS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.